GETTING MY ABBV-744 BRD4 INHIBITOR CLINICAL EFFICACY IN REFRACTORY CANCERS TO WORK

The existing work examined the potential of employing ARV-825 and ABBV-744 to boost the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in each p53 wild-form (WT) breast tumor cells As well as in cells missing purposeful p53 both by itself or in combination with tamoxifen, while the effectiveness of ABBV-744